

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.



June 9, 2026

Company name: Kumiai Chemical Industry Co., Ltd.
 Representative: Masaru Yokoyama, President
 and Representative Director
 (Prime Market of TSE;
 Securities code: 4996)
 For Inquiry: Koji Yamada, General Manager of
 General Affairs Department
 (Telephone: 81-3-3822-5036)

Announcement of Revisions to the Consolidated Earnings Forecast for the Cumulative Second-quarter (Semi-annual) Period of Fiscal Year Ending October 31, 2026

Kumiai Chemical Industry Co., Ltd. (hereinafter, the “Company”) hereby announces that it has revised the consolidated earnings forecast for the cumulative second-quarter (semi-annual) period of the fiscal year ending October 31, 2026, announced on December 12, 2025, as described below.

1. Revisions to the consolidated earnings forecast for the cumulative second-quarter (semi-annual) period of the fiscal year ending October 31, 2026

(From November 1, 2025 to April 30, 2026)

	Net sales	Operating profit	Ordinary profit	Profit attributable to owners of parent	Basic earnings per share
	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Yen
Previous forecasts (A)	92,800	6,100	8,200	4,400	36.54
Revised forecasts (B)	102,900	10,400	13,700	8,700	72.24
Difference (B-A)	10,100	4,300	5,500	4,300	-
Change (%)	10.9	70.5	67.1	97.7	-
(Reference) Results for the cumulative semi-annual period of the previous fiscal year (Fiscal year ended October 31, 2025)	96,177	9,442	8,291	6,274	52.11

2. Reasons for revisions

For the second-quarter (semi-annual) period of the fiscal year ending October 31, 2026, net sales are expected to significantly exceed the forecast, due to shipments being brought forward in the Agricultural Chemicals and Agriculture-Related Business as a result of sales promotion efforts ahead of the entry of generic versions of our main product, AXEEV, into the U.S. market, as well as strong sales in the Fine Chemicals Business. With regard to profit, both operating profit and ordinary profit are expected to increase significantly, due to higher net sales, as well as the fact that we secured profits by bringing forward shipments of AXEEV. Profit attributable to owners of parent is also expected to increase significantly, despite the posting of extraordinary losses, including impairment losses and restructuring costs.

Regarding our full-year performance, while we anticipate that the escalating tensions and prolonged conflict in the Middle East will impact our business, we are still examining the extent of that impact. Therefore, we have maintained the earnings forecast announced on December 12, 2025. Should it become necessary to revise the forecast based on future performance trends, we will disclose the information promptly.

Notes: 1. The Company expects to post extraordinary losses, including impairment losses and restructuring costs, during the cumulative second-quarter (semi-annual) period of the fiscal year ending October 31, 2026. For further details, please refer to the “Announcement of Posting of Extraordinary Losses” announced today (June 9, 2026).

2. The earnings forecast is based on information currently available, and actual financial results may differ from them due to various factors that may arise in the future.